CardioSignal has closed $10 million Series A funding, led by DigiTx Partners, for additional clinical validation of CardioSignal’s breakthrough technology and the expansion of its commercial efforts.

CardioSignal develops digital technologies and software-as-medical-devices to provide early detection of heart diseases, and provides the first and only technology to detect several major heart diseases with high accuracy using just one clinical modality without any specialized medical equipment.

CardioSignal’s technology harnesses gyroscope and accelerometer motion data from smartphones to measure specific rotational movements of the heart that can be used to accurately detect abnormal heart function. The analysis takes place utilizing a smartphone placed on the patient’s chest for a one-minute measurement. A clinically validated algorithm analyzes the motion data in a secure cloud service and provides immediate results.

The company has 52 patents covering its method and clinical algorithms, which are based on gyrocardiography and have been heavily researched and documented in more than 20 peer-reviewed scientific publications.

This funding enables us to scale a detection and remote monitoring solution for primary care doctors and their patients, supporting the shift in cardiovascular care from treating complications to earlier detection and prevention,” said Juuso Blomster, founder and CEO of CardioSignal.

To view the source version, please click HERE.

en_GBEnglish (UK)